[New Report] Induced Pluripotent Stem Cells Market is estimated to be US$ 3.5 billion by 2032; Growing Prevalence of Diseases and Demand for Therapies to Foster Industrial Growth - By PMI
28 juin 2023 11h05 HE
|
PMI
Covina, June 28, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of “Induced Pluripotent Stem Cells Market accounted for US$ 1.8 billion in 2022 and is estimated to be...
Organoids and Spheroids Market is estimated to be US$ 1234.51 Million by 2032 with a CAGR of 8.4% during the forecast period 2032 - By PMI
11 oct. 2022 08h54 HE
|
PMI
Covina, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Organoids and Spheroids are 3D cell cultures which are cultured by different techniques. Organoids helps in studying cell interaction in organ, drug...
aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810
14 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Global Bio safety Testing Market is Estimated to be US$ 10.5 Billion by 2029 with a CAGR of 13.1% during the forecast Period - PMI
09 juin 2020 10h35 HE
|
PMI
Covina, CA, June 09, 2020 (GLOBE NEWSWIRE) -- The global bio safety testing market accounted for US$ 3.1 billion in 2019 and is estimated to be US$ 10.5 billion by 2029 and is anticipated to...
Mesoblast Chairman's Address to 2015 Annual General Meeting
22 oct. 2015 02h00 HE
|
Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting.
This has been another exciting and productive year in the history of our...
Mesoblast Unveils Path to Bring Its Key Products to Market
25 août 2014 20h27 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
FDA Agreement on Mesoblast's Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells
12 févr. 2013 20h28 HE
|
Mesoblast
MELBOURNE, Australia, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast...